JANE IWEBO: Open Payments
NPI 1285296384 · SALISBURY, MD. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,375 in 55 payments from 11 companies in 2025. Trend: 2023 $488 · 2024 $705 · 2025 $1,375
Food & beverage: $1,375
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 15 | $350 |
| Neurocrine BioSciences, Inc. | 6 | $241 |
| Vanda Pharmaceuticals Inc. | 9 | $222 |
| Otsuka America Pharmaceutical, Inc. | 7 | $183 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 4 | $95 |
| Janssen Pharmaceuticals, Inc | 3 | $69 |
| Teva Pharmaceuticals USA, Inc. | 3 | $59 |
| Alkermes, Inc. | 2 | $47 |
| Exact Sciences Corporation | 3 | $44 |
| Axsome Therapeutics, Inc. | 2 | $39 |
Products named: VRAYLAR, INGREZZA, HETLIOZ, CAPLYTA, ABILIFY MAINTENA, SPRAVATO, ABILIFY ASIMTUFII, REXULTI.
Industry payments across MD — which companies pay providers there.
